

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **RENHENG Enterprise Holdings Limited**

**仁恒實業控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3628)**

### **APPOINTMENT OF EXECUTIVE DIRECTOR**

#### **APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of RENHENG Enterprise Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce the appointment of Mr. Wen Yuan (“**Mr. Wen**”) as an executive Director with effect from 6 December 2024.

Mr. Wen, aged 56, obtained a bachelor’s degree in Chinese Language and Literature Education from Northeast Normal University in China in June 1996. Mr. Wen was awarded as Senior Economist in Economic Management from Jilin Provincial Personnel Department of China in January 2008.

Mr. Wen joined Jilin Province Baishan City Fusong County Municipal Engineering Company (吉林省白山市撫松縣市政工程公司) from March 1990 to March 1992 and served as the office director. From August 1994 to May 2014, Mr. Wen joined Jilin Province Baishan City Fusong First Pharmaceutical Factory (吉林白山撫松第一製藥廠) and served as general manager to oversee the general affairs of the factory. From May 2014 to December 2020, Mr. Wen joined Sinopharm Pharmaceutical Co., Ltd. (國藥藥材股份有限公司) and served as general manager and acted as the chairman to oversee the general affairs of the company. Prior to joining our Group, Mr. Wen joined China Pharmaceutical Culture Society (中國藥文化研究會) to serve as vice-chairman and was responsible for organizing academic exchange and holding forum lectures since December 2020. Mr. Wen served as vice-president of China Russia Regional Cooperation and Development Investment Fund Management Co., Ltd. (中俄地區合作發展投資基金管理有限責任公司) and was responsible for researching medical equipment and devices and pharmaceutical and energy since December 2023.

Mr. Wen has entered into a letter (the “**Letter of Appointment**”) with the Company for his role as an executive Director with no specific length of service and his term of service shall continue unless and until terminated by either party by giving to the other three months’ prior notice or payment in lieu of notice. Pursuant to the Letter of Appointment, Mr. Wen will hold office until the next annual general meeting of the Company and is eligible for re-election at such meeting, and he will be subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company and in accordance with the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the articles of association of the Company. Mr. Wen is entitled to a director’s fee payable of HK\$120,000 per annum, and a discretionary bonus or other benefits which are based on the performance of the Group and of Mr. Wen. The emolument of Mr. Wen is determined by the remuneration committee of the Company, with delegated responsibility pursuant to the authority given by the shareholders of the Company (the “**Shareholders**”) at the Company’s last annual general meeting and with reference to his duties and responsibilities, experience and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Mr. Wen (i) did not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) did not hold any position with the Company or its subsidiaries; (iii) did not have any relationship with other directors, senior management, substantial or controlling Shareholders; (iv) did not have any interest in the shares of the Company which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (v) there is no other information which is disclosable pursuant to Rule 13.51(2) of the Listing Rules; and (vi) there are no other matters in relation the appointment of Mr. Wen that need to be brought to the attention of the Shareholders.

The Board would like to welcome Mr. Wen on his appointment as executive Director.

By order of the Board  
**RENHENG Enterprise Holdings Limited**  
**Liu Li**  
*Chairman & Chief Executive Officer*

Hong Kong, 6 December 2024

*As at the date of this announcement, the executive Directors are Ms. Liu Li, Ms. Lew Lai Kuen and Mr. Wen Yuan and the independent non-executive Directors are Dr. Lam, Lee G., Mr. Lam Chi Wing and Mr. Wu Wei.*